Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAPTYSBIO, INCANAB · Entity 4640 | Director | February 08, 2019 | February 11, 2019 |
| Blueprint Medicines CorpBPMC · Entity 77326 | Director | June 12, 2024 | June 14, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAPTYSBIO, INC
Report date February 08, 2019 · Filed February 11, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.89 · Expires 2029-02-07 | Direct | 6,000 |
Reported balance
After 2019-02-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-08 · Grant · Acquired 6,000 · Balance 6,000 F1: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on March 8, 2019, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on March 8, 2019, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.
Blueprint Medicines Corp
Report date June 12, 2024 · Filed June 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,026 |
Reported balance
After 2024-06-12 transaction · row 1
1 source rowRow 1 · 2024-06-12 · Grant · Acquired 2,242 · Balance 58,026 F1: The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $106.14 · Expires 2034-06-12 | Direct | 4,570 |
Reported balance
After 2024-06-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-12 · Grant · Acquired 4,570 · Balance 4,570 F2: This option vests with respect to 100% of the shares underlying the option on the earlier of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2: This option vests with respect to 100% of the shares underlying the option on the earlier of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2024 Filed Jun 14, 2024 17:34 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantStock Option (Right to Buy) · Derivative | 4,570 | $0.00 Strike: $106.14 | $0.00 |
DisclosureSEC source: 0001415889-24-016982 · form4-06142024_090653.xml · derivative · entry 2 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,570 Underlying: Common Stock · 4,570 shares Expires 2034-06-12 F2 · derivative.exercise_date: This option vests with respect to 100% of the shares underlying the option on the earlier of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 17:34 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantCommon Stock | 2,242 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-016982 · form4-06142024_090653.xml · nonDerivative · entry 1 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,026 F1 · kind: The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 19:02 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantStock Option (Right to Buy) · Derivative | 5,300 | $0.00 Strike: $63.66 | $0.00 |
DisclosureSEC source: 0001415889-23-010257 · form4-06232023_110609.xml · derivative · entry 2 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,300 Underlying: Common Stock · 5,300 shares Expires 2033-06-21 F2 · derivative.exercise_date: This option vests with respect to 100% of the shares underlying the option on the earlier of (i) June 21, 2024 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 19:02 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantCommon Stock | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-010257 · form4-06232023_110609.xml · nonDerivative · entry 1 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,784 F1 · kind: The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 21, 2024 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 21, 2022 Filed Jun 30, 2022 21:56 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantStock Option (Right to Buy) · Derivative | 5,300 | $0.00 Strike: $50.64 | $0.00 |
DisclosureSEC source: 0001415889-22-007132 · form4-06302022_060618.xml · derivative · entry 2 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,300 Underlying: Common Stock · 5,300 shares Expires 2032-06-21 F2 · derivative.exercise_date: This option vests with respect to 100% of the shares underlying the option on the earlier of (i) June 21, 2023 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 21, 2022 Filed Jun 30, 2022 21:56 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantCommon Stock | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-007132 · form4-06302022_060618.xml · nonDerivative · entry 1 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,184 F1 · kind: The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 21, 2023 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 23, 2022 Filed May 25, 2022 16:05 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,909 | $0.00 Strike: $19.53 | $0.00 |
DisclosureSEC source: 0001415889-22-005656 · form4-05252022_040501.xml · derivative · entry 2 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,909 shares Expires 2026-06-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted on June 23, 2016 and is fully vested. Read SEC document |
| May 23, 2022 Filed May 25, 2022 16:05 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | Exercise / conversionCommon Stock | 10,909 | $19.53 | $213,052.77 |
DisclosureSEC source: 0001415889-22-005656 · form4-05252022_040501.xml · nonDerivative · entry 1 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 16:14 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantStock Option (Right to Buy) · Derivative | 4,500 | $0.00 Strike: $87.13 | $0.00 |
DisclosureSEC source: 0001179110-21-006414 · edgar.xml · derivative · entry 2 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires 2031-06-02 F2 · derivative.exercise_date: This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 2, 2022. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 16:14 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantCommon Stock | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-006414 · edgar.xml · nonDerivative · entry 1 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,675 F1 · kind: The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 2, 2022. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 16:17 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 1,389 | $92.06 | $127,871.34 |
DisclosureSEC source: 0001179110-20-010226 · edgar.xml · nonDerivative · entry 3 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,425 F1 · kind: Effected pursuant to a trading plan adopted on February 27, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.89 to $92.24 per share. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 16:17 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 4,530 | $92.88 | $420,746.40 |
DisclosureSEC source: 0001179110-20-010226 · edgar.xml · nonDerivative · entry 2 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,814 F1 · kind: Effected pursuant to a trading plan adopted on February 27, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.39 to $93.35 per share. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 16:17 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 3,896 | $93.68 | $364,977.28 |
DisclosureSEC source: 0001179110-20-010226 · edgar.xml · nonDerivative · entry 1 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,344 F1 · kind: Effected pursuant to a trading plan adopted on February 27, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.36 to $94.35 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) to this Form 4. Read SEC document |
| September 17, 2020 Filed Sep 21, 2020 16:21 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 500 | $80.00 | $40,000.00 |
DisclosureSEC source: 0001179110-20-009900 · edgar.xml · nonDerivative · entry 1 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,240 F1 · kind: Effected pursuant to a trading plan adopted on February 27, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 16:25 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 600 | $81.02 | $48,612.00 |
DisclosureSEC source: 0001179110-20-008109 · edgar.xml · nonDerivative · entry 2 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,740 F1 · kind: Effected pursuant to a trading plan adopted on February 27, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.00 to $81.07 per share. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 16:25 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 25,407 | $80.44 | $2,043,739.08 |
DisclosureSEC source: 0001179110-20-008109 · edgar.xml · nonDerivative · entry 1 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,340 F1 · kind: Effected pursuant to a trading plan adopted on February 27, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.96 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| July 02, 2020 Filed Jul 6, 2020 18:30 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 2,825 | $80.13 | $226,367.25 |
DisclosureSEC source: 0001104659-20-081384 · a4.xml · nonDerivative · entry 2 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,747 F1 · kind: Effected pursuant to a trading plan adopted on February 27, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.50 per share. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 18:30 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 1,300 | $80.21 | $104,273.00 |
DisclosureSEC source: 0001104659-20-081384 · a4.xml · nonDerivative · entry 1 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,572 F1 · kind: Effected pursuant to a trading plan adopted on February 27, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.03 to $80.47 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 16:08 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantStock Option (Right to Buy) · Derivative | 4,500 | $0.00 Strike: $76.24 | $0.00 |
DisclosureSEC source: 0001179110-20-007790 · edgar.xml · derivative · entry 2 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires 2030-06-24 F2 · derivative.exercise_date: This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 24, 2021. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 16:08 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantCommon Stock | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-007790 · edgar.xml · nonDerivative · entry 1 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,872 F1 · kind: The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 24, 2021. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 16:10 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 400 | $80.00 | $32,000.00 |
DisclosureSEC source: 0001179110-20-007760 · edgar.xml · nonDerivative · entry 1 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,622 F1 · kind: Effected pursuant to a trading plan adopted on February 27, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 16:13 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 13,017 | $80.29 | $1,045,134.93 |
DisclosureSEC source: 0001179110-20-007717 · edgar.xml · nonDerivative · entry 2 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,022 F2 · kind: Effected pursuant to a trading plan adopted on February 27, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.96 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 16:13 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | Exercise / conversionRestricted Stock Units · Derivative | 1,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-007717 · edgar.xml · derivative · entry 3 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,312 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: On June 19, 2019, the reporting person was granted 1,312 restricted stock units. These restricted stock units are fully vested. F4 · derivative.expiration_date: On June 19, 2019, the reporting person was granted 1,312 restricted stock units. These restricted stock units are fully vested. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 16:13 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | Exercise / conversionCommon Stock | 1,312 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-007717 · edgar.xml · nonDerivative · entry 1 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,039 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 15, 2020 Filed May 19, 2020 16:31 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GiftCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-006304 · edgar.xml · nonDerivative · entry 1 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,727 Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 16:18 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GiftCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-009748 · edgar.xml · nonDerivative · entry 1 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,727 Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 16:37 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantRestricted Stock Units · Derivative | 1,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-007984 · edgar.xml · derivative · entry 2 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,312 Underlying: Common Stock · 1,312 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 19, 2020. F3 · derivative.expiration_date: The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 19, 2020. Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 16:37 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantStock Option (Right to Buy) · Derivative | 4,875 | $0.00 Strike: $96.77 | $0.00 |
DisclosureSEC source: 0001179110-19-007984 · edgar.xml · derivative · entry 1 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,875 Underlying: Common Stock · 4,875 shares Expires 2029-06-19 F1 · derivative.exercise_date: This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 19, 2020. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 17:11 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 25,000 | $90.36 | $2,259,000.00 |
DisclosureSEC source: 0001179110-19-007778 · edgar.xml · nonDerivative · entry 1 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,727 F1 · kind: Effected pursuant to a trading plan adopted on March 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.00 to $90.90 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 18:00 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 300 | $81.96 | $24,588.00 |
DisclosureSEC source: 0001179110-19-007732 · edgar.xml · nonDerivative · entry 5 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,727 F1 · kind: Effected pursuant to a trading plan adopted on March 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.90 to $82.07 per share. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 18:00 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 2,000 | $82.45 | $164,900.00 |
DisclosureSEC source: 0001179110-19-007732 · edgar.xml · nonDerivative · entry 4 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,027 F1 · kind: Effected pursuant to a trading plan adopted on March 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.08 to $83.07 per share. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 18:00 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 5,200 | $83.83 | $435,916.00 |
DisclosureSEC source: 0001179110-19-007732 · edgar.xml · nonDerivative · entry 3 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,027 F1 · kind: Effected pursuant to a trading plan adopted on March 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.18 to $84.16 per share. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 18:00 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 6,300 | $84.66 | $533,358.00 |
DisclosureSEC source: 0001179110-19-007732 · edgar.xml · nonDerivative · entry 2 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,227 F1 · kind: Effected pursuant to a trading plan adopted on March 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.21 to $85.17 per share. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 18:00 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 11,200 | $85.75 | $960,400.00 |
DisclosureSEC source: 0001179110-19-007732 · edgar.xml · nonDerivative · entry 1 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,527 F1 · kind: Effected pursuant to a trading plan adopted on March 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.18 to $86.17 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) to this Form 4. Read SEC document |
| February 08, 2019 Filed Feb 11, 2019 22:31 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantDirector Stock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $68.89 | $0.00 |
DisclosureSEC source: 0001209191-19-009031 · doc4.xml · derivative · entry 1 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2029-02-07 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on March 8, 2019, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 16:56 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $69.79 | $0.00 |
DisclosureSEC source: 0001179110-18-009000 · edgar.xml · derivative · entry 1 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,318 Underlying: Common Stock · 7,500 shares Expires 2028-06-21 F1 · derivative.exercise_date: This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 21, 2019. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 20:46 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 2,222 | $90.26 | $200,549.05 |
DisclosureSEC source: 0001209191-18-025382 · doc4.xml · nonDerivative · entry 7 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,106 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F9 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $89.93 to $90.69 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 20:46 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 2,803 | $89.42 | $250,631.37 |
DisclosureSEC source: 0001209191-18-025382 · doc4.xml · nonDerivative · entry 6 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,328 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F8 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $88.91 to $89.87 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 20:46 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 4,250 | $88.30 | $375,267.35 |
DisclosureSEC source: 0001209191-18-025382 · doc4.xml · nonDerivative · entry 5 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,131 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F7 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $87.91 to $88.90 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 20:46 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 9,425 | $87.46 | $824,340.66 |
DisclosureSEC source: 0001209191-18-025382 · doc4.xml · nonDerivative · entry 4 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,381 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F6 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $86.91 to $87.895 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 20:46 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 1,390 | $86.15 | $119,752.95 |
DisclosureSEC source: 0001209191-18-025382 · doc4.xml · nonDerivative · entry 3 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,806 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $85.75 to $86.73 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 20:46 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 10,310 | $85.11 | $877,491.32 |
DisclosureSEC source: 0001209191-18-025382 · doc4.xml · nonDerivative · entry 2 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 291,196 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $84.75 to $85.74 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 20:46 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 2,600 | $84.18 | $218,879.96 |
DisclosureSEC source: 0001209191-18-025382 · doc4.xml · nonDerivative · entry 1 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,506 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $83.69 to $84.64 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 17:15 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 4,613 | $86.35 | $398,332.55 |
DisclosureSEC source: 0001179110-18-003315 · edgar.xml · nonDerivative · entry 4 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,727 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 19, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.16 to $86.54 per share. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 17:15 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 5,527 | $86.92 | $480,406.84 |
DisclosureSEC source: 0001179110-18-003315 · edgar.xml · nonDerivative · entry 3 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,340 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 19, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.56 to $87.55 per share. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 17:15 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 5,264 | $88.20 | $464,284.80 |
DisclosureSEC source: 0001179110-18-003315 · edgar.xml · nonDerivative · entry 2 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,867 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 19, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.72 to $88.60 per share. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 17:15 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 9,596 | $89.03 | $854,331.88 |
DisclosureSEC source: 0001179110-18-003315 · edgar.xml · nonDerivative · entry 1 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,131 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 19, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.62 to $89.61 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through(5) to this Form 4. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:08 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionSeries C Preferred Stock Warrant (right to buy) · Derivative | 16,483 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001209191-18-011264 · doc4.xml · derivative · entry 2 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,843 shares Expires 2018-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Immediately prior to the closing of the Issuer's initial public offering, the warrant became exercisable for shares of common stock. F2 · derivative.exercise_date: This warrant is exercisable at any time. F1 · derivative.underlying: Immediately prior to the closing of the Issuer's initial public offering, the warrant became exercisable for shares of common stock. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:08 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 16,483 | $4.55 | $74,997.65 |
DisclosureSEC source: 0001209191-18-011264 · doc4.xml · nonDerivative · entry 1 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,106 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering, the warrant became exercisable for shares of common stock. Read SEC document |
| February 02, 2018 Filed Feb 6, 2018 21:11 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantDirector Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $104.81 | $0.00 |
DisclosureSEC source: 0001209191-18-007830 · doc4.xml · derivative · entry 1 Lydon Nicholas · CIK 0001639935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2028-02-01 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on March 2, 2018, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.